B7-1/CD80 Fc Chimera Protein, Mouse,UA BIOSCIENCE_specification/price/image

Product Detail
Company Profile

Product Specification

Species	Mouse
Synonyms	B7,B7.1,BB1,CD28LG,CD28LG1,LAB7
Accession	Q00609-1
Amino Acid Sequence	Val38-Lys245 with Human IgG1 Fc at the C-Terminus
Expression System	HEK293
Molecular Weight	70-90kDa (Reducing)
Purity	>95% by SDS-PAGE, RP-HPLC&SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	Human IgG1 Fc
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, pH7.4, 5% trehalose
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	1.Carin C. Stamper, Yan Zhang, James F. Tobin,David V. Erbe, Shinji Ikemizu, Simon J. Davis, Mark L. Stahl, Jasbir Seehra,William S. Somers & Lidia Mosyak: Crystal structure of the B7-1/CTLA-4complex that inhibits human immune responses, Nature volume 410, pages608–611 (2001).

Background

CD80, the first identified member of the B7 family, is a protein that is widely expressed across a variety of tissues and is also found on some malignant tumor cells. This distribution suggests a potential mechanism by which tumor cells can evade the immune system. Recognized as a potent costimulatory molecule, CD80 plays a significant role in how immune cells regulate malignant growth.
CD80 is upregulated in response to cellular stress and is essential for effective immune surveillance, particularly during the process of carcinogenesis. Studies have reported that a low surface expression of CD80 on colon carcinoma cells can be an immune evasion mechanism. Conversely, in colorectal cancers (CRC) with high-frequency microsatellite instability (MSI), a subtype known for its immunogenicity and association with better prognosis, CD80 expression is often increased.
Both in vivo and in vitro research has demonstrated that increased CD80 expression on the surface of tumor cells can effectively activate antitumor immune responses. However, during tumor progression, the expression of CD80 is frequently diminished, possibly due to selective pressures exerted by the immune system.
Given these findings, enhancing CD80 expression in tumors is a strategy that urgently needs to be explored for the development of effective cancer immunotherapies.

AntBio is a biotechnology group company dedicated to serving life sciences, aiming to help scientists accelerate research and improve work efficiency. AntBio provides comprehensive and high-quality reagent tools for basic research, drug development, and diagnosis, including research grade antibodies, proteins, biochemical reagents, and assay kits. These research tools are widely used in different segments of life science research. The group company currently consists of three brands, Absin, Starter-Bio and UA-Bio.